Funding Opportunity RFA-AI-24-017 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research that 1) defines associations between variations in human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, 2) elucidates mechanisms underlying these associations with the goal of advancing therapeutic opportunities, and/or 3) validates association data in order to improve the predictive power of clinical disease screening.

Funding Opportunity RFA-DK-25-010 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis. CF Research and Translation Core Centers support three primary research-related activities: Research Core services; a Pilot and Feasibility program; and an Administrative Core with an enrichment program. Core Centers provide shared resources to support research to develop and test new therapies for CF and to foster collaborations among institutions with a strong existing research base in CF. The NIDDK currently supports seven CF Research and Translation Centers located at institutions with documented programs of research excellence in basic and clinical CF Research. Information about the currently funded CF Research and Translation Centers may be found at: https://www.niddk.nih.gov/research-funding/research-programs/cystic-fibrosis-research-translation-centers or https://www.cysticfibrosiscenters.org/.

Funding Opportunity RFA-CA-24-023 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This NOFO seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.

Funding Opportunity RFA-CA-24-022 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

Notice NOT-CA-24-040 from the NIH Guide for Grants and Contracts

£42,557 per annum: APHA: This post is based in the Virology department, which is a multi-disciplinary department with internationally recognised.... Weybridge

Notice NOT-HD-24-024 from the NIH Guide for Grants and Contracts

George Washington University: I. DEPARTMENT INFORMATION Job Description Summary: Founded in 1824, the GW School of Medicine and Health Sciences (SMHS) is the 11th oldest medical... Washington, Washington DC

Leidos: Are you looking for a career that will make an impact? The Leidos Health & Civil Sector is currently looking for a Bioinformatics Engineer to suppo... Frederick, Maryland

Hebrew SeniorLife: The Marcus Institute for Aging Research is actively seeking a highly qualified and motivated Post-Doctoral Research Fellow and computational biolog... Roslindale, Massachusetts

AbbVie: Key Responsibilities Engineer, maintain, & improve upon pipeline code base for bioinformatics processing & analysis of various genomics data types... Cambridge, Massachusetts

St. Jude Children's Research Hospital: We are seeking a talented, highly motivated Senior Bioinformatics Research Scientist to lead our bioinformatics pipeline and develop innovative sol... Memphis, Tennessee

Guardant Health: About the Role: The Senior Bioinformatics Scientist will join an interdisciplinary team working with an unprecedented set of clinical DNA whole ge... San Diego, California

Guardant Health: About the Role: The Senior Bioinformatics Scientist will join an interdisciplinary team working with an unprecedented set of clinical DNA whole ge... Palo Alto, California

Notice NOT-DC-24-028 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-108 from the NIH Guide for Grants and Contracts

Notice NOT-OH-24-011 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-036 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-153 from the NIH Guide for Grants and Contracts. The purpose of the Worta McCaskill-Stevens K12 funding opportunity is to support institutional career development awards designed to prepare newly trained clinicians who have made a commitment to independent research careers in community oncology or cancer prevention, and to facilitate their transition to more advanced support mechanisms or independent research funding (e.g., K08, R03, R21, R01). The NOFO will allow the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; or proposing a separate ancillary study to an existing prevention, screening or control clinical trial; or proposing to gain research experience in a community-based clinical trial led by another investigator; or proposing to serve as leader of innovative clinical trial approaches that expand engagement of underserved or underrepresented communities in cancer clinical research, as part of their research and career development.